Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!